A new series of analogs Hexagamavunon-6 (HGV-6) was preparedand screened for antibacterial activity against Streptococcus mutans (ATCC 25175), Escherichia coli (ATCC 25922), Bacillus subtilis(ATCC 6633), Psedomonas aeruginosa (ATCC 27853), Klebsiella pneumoniae and Enterococcus faecalis (ATCC 29212) using disc diffusion method. The antibacterial results showed that 3,5-Bis-(2',4'-dichlorobenzilyden)-N-methyl-4-piperidone (1c) compound display significant inhibition and broad-spectrum antibacterial activity. This is accordance with the in silico evaluation showing that 1c compound has a lower docking score than both 1a and 1b compound. None of the tested compounds was as active as the reference standard drug Amoxicillin.
Key words: Analog curcumin; Hexagamavunon-6; 3,5-Bis-(2',4'-dichlorobenzilyden)-N-methyl-4-piperidone; antibacterials activity; disc diffusion.
|
